Announcements Trials
Browse Landscape

Phase

Phase 1 37Phase 2 33Phase 3 31Phase 1/2 13Phase 4 3

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 2Genitourinary 1Breast 1

Conditions

Ovarian Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Breast Neoplasms 1BRCA or HRR+ Mutated Ovarian Cancer Patients 1

Interventions

Zoledronic Acid 23Bevacizumab 13nilotinib 12Docetaxel 12Paclitaxel 11Everolimus 11Letrozole 10Imatinib Mesylate 10Capecitabine 10Erlotinib Hydrochloride 9Drug Therapy 9Carboplatin 9pegfilgrastim 8enzalutamide 8Trastuzumab 7Oxycodone 7Nivolumab 7Imiquimod 7Gemcitabine 7Epoetin Alfa 7icotinib 6Rituximab 6Prednisone 6Pemetrexed 6Oxaliplatin 6Leuprolide 6Fulvestrant 6Diclofenac 6Dexamethasone 6Cisplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × INDUSTRY × olaparib × Clear all
NCT05457257 2026-04-21

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

AstraZeneca

Phase 4 Active not recruiting
43 enrolled 16 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT04330040 2025-03-10

SOLI

AstraZeneca

Phase 4 Completed
202 enrolled 15 charts
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT02476968 2022-09-10

ORZORA

AstraZeneca

Phase 4 Completed
181 enrolled 24 charts
Gynecologic

BRCA or HRR+ Mutated Ovarian Cancer Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡